GlassScriptPhysician profile
Reena S Mehta
NPI 1316263858
$158,683.94
in general payments reported to CMS, 2019-2025
33 companies · $79K in 2025
The $79K reported for 2025 was more than what 97% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $447 · 2020: $527 · 2021: $1,135 · 2022: $13K · 2023: $30K · 2024: $35K · 2025: $79K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $115K · Travel and Lodging: $14K · Food and Beverage: $9,444 · Consulting Fee: $5,049 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $115,095.00 |
| Travel and Lodging | $14,344.50 |
| Food and Beverage | $9,443.63 |
| Consulting Fee | $5,049.00 |
| Education | $103.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $82,463.33 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $45,735.38 | 2019-2025 | |
| Amgen INC. | $12,837.20 | 2022-2025 | Tezspire, Actimmune |
| Genentech USA, INC. | $12,207.42 | 2019-2025 | Xolair |
| Glaxosmithkline, LLC. | $1,976.00 | 2019-2025 | Trelegy Ellipta, Nucala |
| Regeneron Healthcare Solutions, INC. | $528.57 | 2019-2025 | Dupixent |
| Pfizer INC. | $465.85 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $407.49 | 2021-2025 | Cuvitru |
| Abbvie INC. | $360.96 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $269.55 | 2021-2025 | |
| Galderma Laboratories, L.P. | $256.51 | 2024-2025 | Nemluvio |
| Kaleo, INC. | $146.44 | 2020-2024 | Auvi-Q |
| Aimmune Therapeutics, INC. | $129.61 | 2021-2022 | |
| Grifols USA, LLC | $114.99 | 2021-2024 | Xembify |
| Alk-Abello, INC | $95.66 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $89.70 | 2023-2024 | Hizentra |
| Ars Pharmaceuticals Operations, INC. | $68.31 | 2025 | Neffy |
| Teva Pharmaceuticals USA, INC. | $65.91 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $65.37 | 2023 | |
| Biocryst US Sales Co., LLC | $43.41 | 2021-2025 | Orladeyo |
| Leo Pharma INC. | $41.41 | 2024 | Adbry |
| Hikma Pharmaceuticals USA | $38.00 | 2024 | Ryaltris |
| Phadia US INC. | $34.91 | 2022-2024 | Immunocap |
| Adma Biomanufacturing LLC | $33.63 | 2021 | |
| Optinose US, INC. | $33.00 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.08 | 2020-2021 | |
| Incyte Corporation | $27.26 | 2021 | |
| Azurity Pharmaceuticals, INC. | $25.87 | 2025 | Alvesco |
| Organon LLC | $22.84 | 2025 | Vtama |
| Blueprint Medicines Corporation | $22.55 | 2023 | Ayvakit |
| Pharming Healthcare, INC. | $17.82 | 2025 | Ruconest |
| Shire North American Group INC | $15.94 | 2019 | |
| Cycle Pharmaceuticals INC | $11.97 | 2024 | Sajazir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reena Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.